Christopher M Dobson Selected Research

Intrinsically Disordered Proteins

1/2018	Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.
11/2016	β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces.
3/2016	A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
1/2016	Structural basis of synaptic vesicle assembly promoted by α-synuclein.
1/2016	Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein.
3/2015	Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation.
11/2014	A relationship between the transient structure in the monomeric state and the aggregation propensities of α-synuclein and β-synuclein.
5/2014	Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.
1/2014	Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
9/2010	Structure and properties of a complex of α-synuclein and a single-domain camelid antibody.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher M Dobson Research Topics

Disease

100	Alzheimer Disease (Alzheimer's Disease) 10/2021 - 04/2002
76	Parkinson Disease (Parkinson's Disease) 10/2021 - 12/2002
75	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2022 - 07/2005
25	Amyloidosis 08/2020 - 04/2002
20	Amyloid Plaque 06/2020 - 12/2002
16	Proteostasis Deficiencies 08/2020 - 08/2009
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2019 - 01/2012
6	Synucleinopathies 10/2021 - 12/2014
6	Dementia (Dementias) 01/2021 - 01/2010
5	Nervous System Diseases (Neurological Disorders) 01/2021 - 11/2002
5	Neuroblastoma 01/2021 - 01/2017
4	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2018 - 01/2004
4	Huntington Disease (Huntington's Disease) 01/2018 - 12/2003
3	Brain Diseases (Brain Disorder) 10/2011 - 04/2002
2	Bacterial Infections (Bacterial Infection) 01/2019 - 01/2009
2	Neuroinflammatory Diseases 01/2018 - 01/2013
2	Neoplasms (Cancer) 01/2018 - 01/2009
2	Paralysis (Palsy) 01/2018 - 01/2017
2	Disease Progression 03/2016 - 12/2014
2	Cataract (Cataracts) 01/2004 - 11/2002
2	Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease) 12/2003 - 12/2002
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Multiple System Atrophy 01/2020
1	Muscular Diseases (Myopathy) 12/2019
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 10/2019
1	Pre-Eclampsia (Preeclampsia) 01/2019
1	Parkinsonian Disorders (Parkinsonism) 01/2018
1	Type 2 Diabetes Mellitus (MODY) 06/2017
1	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2017
1	Tauopathies 01/2015
1	Neoplasm Metastasis (Metastasis) 06/2014
1	Atherosclerosis 05/2014
1	Arthritis (Polyarthritis) 05/2014

Drug/Important Bio-Agent (IBA)

124	Proteins (Proteins, Gene)FDA Link 02/2022 - 04/2002
111	Amyloid (Amyloid Fibrils)IBA 10/2021 - 04/2002
67	Peptides (Polypeptides)IBA 01/2021 - 12/2002
60	SynucleinsIBA 10/2021 - 09/2010
18	Muramidase (Lysozyme)IBA 11/2017 - 08/2003
14	alpha-SynucleinIBA 03/2016 - 01/2005
12	Intrinsically Disordered ProteinsIBA 01/2018 - 01/2005
9	Amyloid beta-PeptidesIBA 01/2019 - 10/2008
8	Protein AggregatesIBA 12/2019 - 10/2015
7	LipidsIBA 01/2021 - 01/2017
7	Molecular Chaperones (Chaperone, Molecular)IBA 01/2021 - 10/2011
6	Pharmaceutical PreparationsIBA 11/2020 - 01/2014
5	SolutionsIBA 11/2020 - 09/2005
4	Crystallins (Crystallin)IBA 01/2021 - 01/2004
4	PrionsIBA 01/2021 - 10/2015
4	polyglutamineIBA 01/2018 - 11/2014
3	Biological ProductsIBA 10/2021 - 02/2010
3	Single-Domain AntibodiesIBA 01/2021 - 10/2013
3	CalciumIBA 01/2021 - 03/2006
3	Small Heat-Shock ProteinsIBA 01/2021 - 03/2010
3	DNA-Binding Proteins (DNA Binding Protein)IBA 10/2019 - 01/2016
3	AntibodiesIBA 01/2019 - 01/2017
3	ClusterinIBA 11/2017 - 08/2007
2	Prion ProteinsIBA 01/2021 - 12/2003
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021 - 03/2016
2	Amino Acids FDA Link 01/2021 - 07/2014
2	24-dihydroxy-5-cholestane 24-sulfate 3-N-1(spermine)-7IBA 01/2020 - 01/2018
2	Cytotoxins (Cytolysins)IBA 01/2020 - 01/2019
2	UbiquitinIBA 10/2019 - 11/2017
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 05/2014
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2018 - 11/2017
2	Protein Isoforms (Isoforms)IBA 01/2016 - 11/2015
2	lacmoidIBA 01/2012 - 09/2009
2	Phospholipids (Phosphatides)FDA LinkGeneric 02/2010 - 07/2009
2	Congo RedIBA 09/2009 - 12/2003
1	N-Methylaspartate (NMDA)IBA 01/2021
1	AMPA Receptors (AMPA Receptor)IBA 01/2021
1	peptide AIBA 01/2021
1	NeurotoxinsIBA 11/2020
1	Lipid Bilayers (Lipid Bilayer)IBA 10/2020
1	Cystatin CIBA 08/2020
1	Cyclic PeptidesIBA 10/2019
1	Coloring Agents (Dyes)IBA 10/2019
1	Cysteine (L-Cysteine)FDA Link 08/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Fluorescent Dyes (Fluorescent Probes)IBA 12/2018
1	CholesterolIBA 01/2018
1	glucose-regulated proteinsIBA 01/2018
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/2018
1	DipeptidesIBA 11/2017
1	tau Proteins (tau Protein)IBA 11/2017
1	squalamineIBA 01/2017
1	Inosine Diphosphate (IDP)IBA 05/2016
1	MetalsIBA 03/2016
1	IonsIBA 03/2016
1	Bexarotene (LGD1069)FDA Link 02/2016
1	Indicators and Reagents (Reagents)IBA 01/2016
1	Huntingtin ProteinIBA 06/2015
1	Chemokine CX3CL1IBA 01/2015
1	Cell Surface ReceptorsIBA 11/2014
1	Hypochlorous Acid (Hypochlorite)IBA 05/2014
1	SulfonamidesIBA 01/2014
1	Immunoglobulin FragmentsIBA 10/2013
1	SeleniumIBA 06/2012
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2012

Therapy/Procedure

6	Therapeutics 10/2021 - 03/2003
2	Immunotherapy 01/2017 - 12/2014